
    
      The initial purpose of the study is to determine the largest amount of ensartinib that can be
      safely given to humans. An expansion phase will be conducted to assess the preliminary
      anti-tumor activity in ALK-positive non-small cell lung cancer once the recommended Phase 2
      dose has been established.
    
  